Private Equity
Drive Capital has raised $558 million for two venture-capital funds, according to filings with the SEC.
1 min read · 22 April 2019
La Jolla, California-based Avidity Biosciences, a biotech company, has secured $15 million in funding as part of a licensing and research agreement with Eli Lilly and Company. According to terms of the deal, Avidity will receive an upfront payment of $20 million and is also eligible to receive up to about $405 million for development, regulatory and commercialization milestones.
1 min read · 22 April 2019
Math Venture Partners has raised over $44 million for its second fund, according to an SEC filing. Based in Chicago, the venture firm invests in technology and digital companies.
1 min read · 22 April 2019
1 min read · 22 April 2019
3 min read · 19 April 2019
Joe Montana's Liquid 2 Ventures has raised $37.7 million toward a second venture-capital fund, according to a filing with the SEC.
1 min read · 19 April 2019
Grit Labs has set out to raise a venture-capital fund, according to a filing with the SEC.
1 min read · 19 April 2019
1 min read · 19 April 2019
Canadian healthcare technology venture capital firm iGan Partners has secured $100 million in the final close of its first fund, iGan Fund I. The fund was backed by family offices and high-net-worth investors. Fund I will focus on early-stage companies in digital health, medical devices, healthcare IT and artificial intelligence, and other sectors. Toronto-based iGan Partners is led by Managing Partner Sam Ifergan, who founded the firm in 2013, and Partner Joel Finlayson. Its recent deals include a $2 million seed financing of OrbCare, a Toronto-based unified health cloud platform, and a $5 million Series A financing of Rna Diagnostics, a Toronto-based cancer therapy guidance platform. Both rounds were led by iGan Partners.
2 min read · 18 April 2019
New York and Austria-based Hookipa Pharma, a developer of immunotherapeutics, has raised $84 million for its IPO after pricing its 6 million shares at $14 per share. The stock began trading April 18, 2019 on the NASDAQ under the ticker symbol “HOOK." BofA Merrill Lynch, SVB Leerink and RBC Capital Markets are the lead underwriters. Hookipa's pre-IPO backers included HBM Partners, Hillhouse Capital, Sirona Capital, Gilead, Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners.
3 min read · 18 April 2019
